Literature DB >> 16372548

Adverse oral sequelae to bisphosphonate administration.

Mark Marunick1, Robert Miller, Sara Gordon.   

Abstract

Osteonecrosis of the jaws following the administration of bisphosphonate class drugs, both intravenous and oral, has recently been reported in the literature. A case series of five patients is presented. The clinical presentation, management, and proposed etiology of this adverse reaction are reviewed. Recommendations for identifying patients who may be at risk via medical history, present and past medications, specific drugs involved and recommended precautions involving various dental interventions are also discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16372548

Source DB:  PubMed          Journal:  J Mich Dent Assoc        ISSN: 0026-2102


  5 in total

Review 1.  Case series in drug safety: a review to determine characteristics and quality.

Authors:  Claire Nour Abou Chakra; Antoine Pariente; Marion Pinet; Lenhangmbong Nkeng; Nicholas Moore; Yola Moride
Journal:  Drug Saf       Date:  2010-12-01       Impact factor: 5.606

Review 2.  Bisphosphonates in multiple myeloma: an updated network meta-analysis.

Authors:  Rahul Mhaskar; Ambuj Kumar; Branko Miladinovic; Benjamin Djulbegovic
Journal:  Cochrane Database Syst Rev       Date:  2017-12-18

Review 3.  Factors associated with osteonecrosis of the jaw among bisphosphonate users.

Authors:  Lisa M Hess; Joanne M Jeter; Marge Benham-Hutchins; David S Alberts
Journal:  Am J Med       Date:  2008-06       Impact factor: 4.965

Review 4.  Osteonecrosis of the jaw.

Authors:  Philip N Sambrook; Peter Ebeling
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

Review 5.  Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws.

Authors:  Nicolau Conte-Neto; Alliny Souza Bastos; Rosemary Adriana Chierici Marcantonio; Elcio Marcantonio Junior
Journal:  Head Face Med       Date:  2012-03-01       Impact factor: 2.151

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.